Objective: The primary aim of medical care and surgery for mitral valve disease is to improve the overall functional capacity and health of patients.
Aim: To assess whether there was an actual improvement in quality of life (QOL) of patients 3 months following primary mitral valve repair (MRr) or mitral valve replacement (MVR).
Methods: Prospective study of 61 consecutive patients (34 males, mean age 64+/-12) who underwent primary, isolated mitral valve repair (MRr, n=40) or mitral valve replacement (MVR, n = 21) from April 1997 to October 1998. QOL parameters using the validated short form 36 (SF-36) questionnaire were determined before and at 3 months after surgery and analysed using the Wilcoxon matched pairs rank test.
Results: Mean QOL scores (scale 0-100) for all patients following mitral valve surgery showed clinical and statistically significant improvement in seven of eight QOL parameters, namely (i) physical function (post, 60+/-31 vs. pre, 44+/-29; P = 0.0001); (ii) role limitation due to physical function (50+/-42 vs. 23+/-36; P = 0.0002); (iii) social function (76+/-31 vs. 59+/-36; P = 0.0006); (iv) role limitation due to emotional problems (65+/-42 vs. 44+/-45; P = 0.003); (v) energy (57+/-24 vs. 40+/-24; P < 0.0001); (vi) mental health (73+/-20 vs. 66+/-21; P = 0.007); and (vii) general health perception (68+/-19 v 56+/-22; P = 0.0001); but not pain (73+/-29 v 71+/-30; P = 0.4). Following MRr there was significant improvement in seven of eight QOL parameters and following MVR there was significant improvement in three of eight QOL parameters. Whilst patients with ejection fraction > or = 50% showed significant improvement in seven of eight QOL parameters, there was no significant improvement in any QOL parameters in patients with impaired left ventricular (LV) function. Similarly, patients with mitral regurgitation with end-systolic dimensions of > or = 45 mm showed no significant improvement in any QOL parameters at 3 months follow-up.
Conclusions: Our study suggests that following mitral valve surgery there was significant improvement in the QOL of patients especially in those patients requiring mitral valve repair. However, patients with impaired LV function and those with MR with end-systolic dimensions > or = 45 mm were unlikely to demonstrate a significant improvement in QOL at 3 months follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1010-7940(01)00952-6 | DOI Listing |
Eur Heart J Open
January 2025
Department of Medicine, Cardiovascular Precision Medicine Center, Hadassah Hebrew University Medical Center, P.O. Box 12000, 9112001 Jerusalem, Israel.
Aims: Mitral valve prolapse (MVP) is a common valvular disorder associated with significant morbidity and mortality, with a strong genetic basis. This study aimed to identify a mutation in a family with MVP and to characterize the valve phenotype in LTBP2 knockout (KO) mice.
Methods And Results: Exome sequencing and segregation analysis were performed on a large family with MVP.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Cardiology, National University Heart Centre Singapore, Singapore.
Introduction: The severity of mitral stenosis (MS) is commonly assessed using mitral valve area (MVA) measured with transthoracic echocardiography (TTE). The dimensionless index (DI) of mitral valve (MV) was recently studied in degenerative MS. We evaluated DI MV in rheumatic MS and studied its relationship with clinical outcomes.
View Article and Find Full Text PDFCureus
December 2024
Department of Neurosurgery, International University of Health and Welfare Narita Hospital, Narita, JPN.
Infectious intracranial aneurysms (IIAs) are rare lesions with fragile arterial walls located within the aneurysms, carrying a high risk of rupture. Standard management often involves antibiotic therapy and parent artery occlusion; however, the latter carries a significant risk of cerebral infarction. This report presents a case of an unruptured IIA following cerebral infarction, successfully treated with coil embolization while preserving the parent artery.
View Article and Find Full Text PDFJ Am Coll Cardiol
February 2025
Center for Interventional Programs, UCLA Health System, and the UCLA Cardiac Arrhythmia Center & EP Programs David Geffen School of Medicine, Los Angeles, California, USA. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!